Related Experiment Video

Updated: Jun 16, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy

Eleftheria Kampouri1,2, Patrick Flaherty1, Hu Xie3

  • 1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.

Blood Advances
|April 9, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.4K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.2K

Related Experiment Videos

Last Updated: Jun 16, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.4K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.2K

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...

Articles linked to this work by shared authors, journal, and citation graph.

Association between patient-reported symptoms and clinical outcomes in R/R CLL.

Blood advances·2026

Prognostic Models for Optimal and Improved Health-Related Quality-of-Life Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.

JCO clinical cancer informatics·2026

Cytomegalovirus-Cell-Mediated Immunity Assays for the Prevention and Management of Cytomegalovirus in Transplant Recipients and Patients Receiving Cellular Therapies.

Transplant infectious disease : an official journal of the Transplantation Society·2026

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.

Blood advances·2026

Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.

Blood advances·2026

A Synthetic, Small Molecule, Allosteric Inhibitor of Human Factor XIa for Thrombosis.

Blood advances·2026

Cumulative Stress Measured by Allostatic Load is Associated with Vaso-Occlusive Episodes in Sickle Cell Disease.

Blood advances·2026

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

Blood advances·2026

A hemoglobin >120g/L trends toward improved survival without increasing vascular events in ESA-treated MDS patients.

Blood advances·2026

Systematic Review and Meta-Analysis of Hypersensitivity Reactions after High-dose Intravenous Iron.

Blood advances·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us